DETERMINING MATRIX METALLOPROTEINASE 9 GENE POLYMORPHISM IN PREECLAMPTIC PREGNANT WOMEN

Thị Thu Hằng Trần, Thanh Thúy Nguyễn

Main Article Content

Abstract

Objectives: To investigate the MMP-9 gene polymorphism (-1562 C>T) in healthy pregnant women and preeclamptic pregnant women at Hanoi Obstetrics and Gynecology Hospital. Subjects and methods: Two groups of pregnant women, including 120 physiologicallly pregnant women (control group) and 120 preeclamptic patients (patient group) from November 2021 to January 2023 at Hanoi Obstetrics and Gynecology Hospital.. Results: The CC, CT and TT genotype rates were 75%, 20,8%, 4,2%, respectively, in the preeclampsia group and 73,3%, 25%, 1,7% in the healthy pregnant women. There was no difference in the genotypes of the MMP-9 gene polymorphism (-1562 C>T) in the two groups of pregnant women with p > 0,05. The frequencies of C allele and T allele in preeclamptic pregnant women are 85,42% and 14,58%, respectively, in healthy pregnant women are 85,8% and 14,2%, respectively, the difference is not statistically significant with 95% confidence. No association between this gene polymorphysim and symptoms of preeclampsia has been found. Conclusion: There was no association between MMP-9 gene polymorphism (-1562 C>T) and preeclampsia in this study.

Article Details

References

1. Gannoun MBA, Raguema N, Zitouni H, et al. MMP-2 and MMP-9 Polymorphisms and Preeclampsia Risk in Tunisian Arabs: A Case-Control Study. J Clin Med. 2021;10(12):2647. doi:10.3390/jcm10122647
2. Timokhina E, Strizhakov A, Ibragimova S, et al. Matrix Metalloproteinases MMP-2 and MMP-9 Occupy a New Role in Severe Preeclampsia. J Pregnancy. 2020;2020: e8369645. doi:10.1155/ 2020/8369645
3. Duley L. The Global Impact of Pre-eclampsia and Eclampsia. Semin Perinatol. 2009;33(3):130-137. doi:10.1053/j.semperi.2009.02.010
4. Palei ACT, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta. 2010;411(11):874-877. doi:10.1016/j.cca.2010.03.002
5. Rahimi Z, Rahimi Z, Shahsavandi MO, Bidoki K, Rezaei M. MMP-9 (-1562 C:T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia. Biomark Med. 2013;7(1):93-98. doi:10.2217/bmm.12.95
6. Gremlich S, Nguyen D, Reymondin D, et al. Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk. J Reprod Immunol. 2007; 74(1): 143-151. doi:10.1016/ j.jri.2007.02.001
7. Luizon MR, Sandrim VC, Palei AC, et al. Epistasis among eNOS, MMP-9 and VEGF maternal genotypes in hypertensive disorders of pregnancy. Hypertens Res. 2012;35(9):917-921. doi:10.1038/hr.2012.60
8. Sun C, Zhang Q, Hu B, Zhang K. Investigation of the association between matrix metalloproteinase-9 genetic polymorphisms and development of pre-eclampsia in Chinese pregnant women. Genet Mol Res GMR. 2016;15(3). doi:10.4238/gmr.15038355